Machine learning to predict high-dose methotrexate-related neutropenia and fever in children with B-cell acute lymphoblastic leukemia

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.
   PubMed Web of Science ®Google Scholar
• Jordaens S, Cooksey L, Bonney S, et al. Serum profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia. Br J Haematol. 2020;189(3):500–512.
   PubMed Web of Science ®Google Scholar
• Larsen EC, Devidas M, Chen S, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children's Oncology Group Study AALL0232. J Clin Oncol. 2016;34(20):2380–2388.
   PubMed Web of Science ®Google Scholar
• Bhojwani D, Sabin ND, Pei D, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014;32(9):949–959.
   PubMed Web of Science ®Google Scholar
• Trama A, Botta L, Foschi R, et al. Survival of European adolescents and young adults diagnosed with cancer in 2000-07: population-based data from EUROCARE-5. Lancet Oncol. 2016;17(7):896–906.
   PubMed Web of Science ®Google Scholar
• Howard SC, McCormick J, Pui CH, et al. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471–1482.
   PubMed Web of Science ®Google Scholar
• Huang X, Fang Q, Rao T, et al. Leucovorin ameliorated methotrexate induced intestinal toxicity via modulation of the gut microbiota. Toxicol Appl Pharmacol. 2020;391:114900.
   PubMed Web of Science ®Google Scholar
• Yousef AM, Farhad R, Alshamaseen D, et al. Folate pathway genetic polymorphisms modulate methotrexate-induced toxicity in childhood acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2019;83(4):755–762.
   PubMed Web of Science ®Google Scholar
• Kapoor G, Sinha R, Abedin S. Experience with high dose methotrexate therapy in childhood acute lymphoblastic leukemia in a tertiary care cancer centre of a developing country. Pediatr Blood Cancer. 2012;59(3):448–453.
   PubMed Web of Science ®Google Scholar
• Gervasini G, de Murillo SG, Jiménez M, et al. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia. Gene. 2017;628:72–77.
   PubMed Web of Science ®Google Scholar
• van Tilburg CM, Sanders EA, Nibbelke EE, et al. Impact of reduced chemotherapy treatment for good risk childhood acute lymphoblastic leukaemia on infectious morbidity*. Br J Haematol. 2011;152(4):433–440.
   PubMed Web of Science ®Google Scholar
• O’Connor D, Bate J, Wade R, et al. Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003. Blood. 2014;124(7):1056–1061.
   PubMed Web of Science ®Google Scholar
• Nearing JT, Connors J, Whitehouse S, et al. Infectious complications are associated with alterations in the gut microbiome in pediatric patients with acute lymphoblastic leukemia. Front Cell Infect Microbiol. 2019;9:28.
   PubMed Web of Science ®Google Scholar
• Razali RH, Noorizhab MNF, Jamari H, et al. Association of ABCC2 with levels and toxicity of methotrexate in Malaysian Childhood acute lymphoblastic leukemia (ALL). Pediatr Hematol Oncol. 2020;37(3):185–197.
   PubMed Web of Science ®Google Scholar
• Zgheib NK, Akra-Ismail M, Aridi C, et al. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia. Pharmacogenet Genomics. 2014;24(8):387–396.
   PubMed Web of Science ®Google Scholar
• Tantawy AA, El-Bostany EA, Adly AA, et al. Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis. 2010;21:28–34.
   PubMed Web of Science ®Google Scholar
• Aráoz HV, D'Aloi K, Foncuberta ME, et al. Pharmacogenetic studies in children with acute lymphoblastic leukemia in Argentina. Leuk Lymphoma. 2015;56(5):1370–1378.
   PubMed Web of Science ®Google Scholar
• Li X, Sui Z, Jing F, et al. Identifying risk factors for high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia. Cancer Manag Res. 2019;11:6265–6274.
   PubMed Web of Science ®Google Scholar
• Giletti A, Esperon P. Genetic markers in methotrexate treatments. Pharmacogenomics J. 2018;18(6):689–703.
   PubMed Web of Science ®Google Scholar
• Cao M, Guo M, Wu DQ, et al. Pharmacogenomics of methotrexate: current status and future outlook. Curr Drug Metab. 2018;19(14):1182–1187.
   PubMed Web of Science ®Google Scholar
• Hu YH, Zhou L, Wang SS, et al. Methotrexate disposition in pediatric patients with acute lymphoblastic leukemia: what have we learnt from the genetic variants of drug transporters. Curr Pharm Des. 2019;25(6):627–634.
   PubMed Web of Science ®Google Scholar
• Huang Z, Tong HF, Qian JC, et al. Association of folypolyglutamate synthetase (FPGS) gene polymorphism with blood drug concentration as well as adverse reactions of methotrexate in children with acute leukaemia. Biomed Res. 2017;28:478–483.
   Google Scholar
• Liu SG, Li ZG, Cui L, et al. Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population. Leuk Lymphoma. 2011;52(6):1030–1040.
   PubMed Web of Science ®Google Scholar
• Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019;380(14):1347–1358.
   PubMed Web of Science ®Google Scholar
• Naushad SM, Dorababu P, Rupasree Y, et al. Classification and regression tree-based prediction of 6-mercaptopurine-induced leucopenia grades in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2019;83(5):875–880.
   PubMed Web of Science ®Google Scholar
• Kang X, Zheng L, Zeng W, et al. Risk factors for post-ERCP pancreatitis in high-risk patients receiving post-procedure rectal indomethacin. J Gastrointest Surg. 2018;22(11):1903–1910.
   PubMed Web of Science ®Google Scholar
• Oyaga-Iriarte E, Insausti A, Sayar O, et al. Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters. J Pharmacol Sci. 2019;140(1):20–25.
   PubMed Web of Science ®Google Scholar
• Rajula HSR, Verlato G, Manchia M, et al. Comparison of conventional statistical methods with machine learning in medicine: diagnosis, Drug Development, and Treatment. Medicina. 2020;56:455.
   PubMedGoogle Scholar
• Li Q, Fan QL, Han QX, et al. Machine learning in nephrology: scratching the surface. Chin Med J (Engl). 2020;133:687–698.
   PubMed Web of Science ®Google Scholar
• Khoury N, Attal F, Amirat Y, et al. Data-driven based approach to aid Parkinson's disease diagnosis. Sensors (Basel). 2019;19(2):242.
   PubMed Web of Science ®Google Scholar
• Cherkassky V. The nature of statistical learning theory. IEEE Trans Neural Netw. 1997;8(6):1564.
   PubMedGoogle Scholar
• Ben-Hur A, Weston J. A user's guide to support vector machines. Methods Mol Biol. 2010;609:223–239.
   PubMedGoogle Scholar
• Mansour NA, Saleh AI, Badawy M, et al. Accurate detection of Covid-19 patients based on Feature Correlated Naïve Bayes (FCNB) classification strategy. J Ambient Intell Humaniz Comput. 2021;1–33.
   PubMed Web of Science ®Google Scholar
• Wilson TJ, Howe BM, Stewart SA, et al. Clinicoradiological features of intraneural perineuriomas obviate the need for tissue diagnosis. J Neurosurg. 2018;129(4):1034–1040.
   PubMed Web of Science ®Google Scholar
• Nithya B, Ilango V. Evaluation of machine learning based optimized feature selection approaches and classification methods for cervical cancer prediction. SN Appl Sci. 2019;1(6):1–16.
   Web of Science ®Google Scholar
• Liu MM, Wen L, Liu YJ, et al. Application of data mining methods to improve screening for the risk of early gastric cancer. BMC Med Inform Decis Mak. 2018;18(Suppl 5):121.
   PubMedGoogle Scholar
• Li XY, Li JQ, Luo XQ, et al. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol. BMC Cancer. 2021;21(1):59.
   PubMed Web of Science ®Google Scholar
• Yuan X, Yu U, Chen S, et al. Case report: myeloid sarcoma development during treatment for B cell lymphoblastic lymphoma in a Boy with KRAS/NRAS gene mutations. OTT. 2021;14:347–353.
   Google Scholar
• Gervasini G, Mota-Zamorano S. Clinical implications of methotrexate pharmacogenetics in childhood acute lymphoblastic leukaemia. Curr Drug Metab. 2019;20(4):313–330.
   PubMed Web of Science ®Google Scholar
• Zhou H, Li L, Yang P, et al. Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants? BMC Cancer. 2018;18(1):516.
   PubMedGoogle Scholar
• Yang JJ, Landier W, Yang W, et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol. 2015;33(11):1235–1242.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52:e56-93.
   PubMed Web of Science ®Google Scholar
• van Kooten Niekerk PB, Schmiegelow K, Schroeder H. Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate. Eur J Haematol. 2008;81:391–398.
   PubMed Web of Science ®Google Scholar
• Li MJ, Chang HH, Yang YL, et al. Infectious complications in children with acute lymphoblastic leukemia treated with the Taiwan Pediatric Oncology Group protocol: a 16-year tertiary single-institution experience. Pediatr Blood Cancer. 2017;64(10):e26535.
   Web of Science ®Google Scholar
• He H, Yang B, Garcia EA, et al. ADASYN: Adaptive synthetic sampling approach for imbalanced learning. IJCNN 2008 (IEEE World Congress on Computational Inteligence), IJCNN 2008. IEEE International Joint Conference on Neural Networks; 2008.
   Google Scholar
• Chawla NV, Bowyer KW, Hall LO, et al. SMOTE: synthetic minority over-sampling technique. JAIR. 2002;16:321–357.
   Web of Science ®Google Scholar
• Han H, Wang WY, Mao BH. Borderline-SMOTE: a new over-sampling method in imbalanced data sets learning. Lecture Notes in Computer Science. 2005;3644(1):878–887.
   Google Scholar
• Jia C, Zuo Y. S-SulfPred: a sensitive predictor to capture S-sulfenylation sites based on a resampling one-sided selection undersampling-synthetic minority oversampling technique. J Theor Biol. 2017;422:84–89.
   PubMed Web of Science ®Google Scholar
• Koch G, Pfister M, Daunhawer I, et al. Pharmacometrics and machine learning partner to advance clinical data analysis. Clin Pharmacol Ther. 2020;107(4):926–933.
   PubMed Web of Science ®Google Scholar
• Yang T, Yang Y, Jia Y, et al. Dynamic prediction of hospital admission with medical claim data. BMC Med Inform Decis Mak. 2019;19(Suppl 1):18.
   PubMedGoogle Scholar
• Sajith M, Pawar A, Bafna V, et al. Serum methotrexate level and side effects of high dose methotrexate infusion in pediatric patients with acute lymphoblastic leukaemia (ALL). Indian J Hematol Blood Transfus. 2020;36(1):51–58.
   PubMed Web of Science ®Google Scholar
• Liu SG, Gao C, Zhang RD, et al. Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia. Oncotarget. 2017;8(23):37761–37772.
   PubMedGoogle Scholar
• Ramsey LB, Bruun GH, Yang W, et al. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res. 2012;22(1):1–8.
   PubMed Web of Science ®Google Scholar
• van de Steeg E, Wagenaar E, van der Kruijssen CM, et al. Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest. 2010;120(8):2942–2952.
   PubMed Web of Science ®Google Scholar
• van de Steeg E, van der Kruijssen CM, Wagenaar E, et al. Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab Dispos. 2009;37(2):277–281.
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, et al. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;57(4):612–619.
   PubMed Web of Science ®Google Scholar
• Radtke S, Zolk O, Renner B, et al. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood. 2013;121(26):5145–5153.
   PubMed Web of Science ®Google Scholar
• Ramsey LB, Panetta JC, Smith C, et al. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood. 2013;121(6):898–904.
   PubMed Web of Science ®Google Scholar
• Treviño LR, Shimasaki N, Yang W, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol. 2009;27(35):5972–5978.
   PubMed Web of Science ®Google Scholar
• Li J, Wang XR, Zhai XW, et al. Association of SLCO1B1 gene polymorphisms with toxicity response of high dose methotrexate chemotherapy in childhood acute lymphoblastic leukemia. Int J Clin Exp Med. 2015;8:6109–6113.
   PubMed Web of Science ®Google Scholar
• Fontanella C, Bolzonello S, Lederer B, et al. Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropenia. Breast Care (Basel). 2014;9(4):239–245.
   PubMed Web of Science ®Google Scholar
• Ammann RA, Bodmer N, Hirt A, et al. Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN study. J Clin Oncol. 2010;28(12):2008–2014.
   PubMed Web of Science ®Google Scholar
• Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228–237.
   PubMed Web of Science ®Google Scholar
• Castagnola E, Fontana V, Caviglia I, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis. 2007;45(10):1296–1304.
   PubMed Web of Science ®Google Scholar
• Dale DC. How I diagnose and treat neutropenia. Curr Opin Hematol. 2016;23:1–4.
   PubMed Web of Science ®Google Scholar
• Xie C, Du R, Ho JW, et al. Effect of machine learning re-sampling techniques for imbalanced datasets in (18)F-FDG PET-based radiomics model on prognostication performance in cohorts of head and neck cancer patients. Eur J Nucl Med Mol Imaging. 2020;47(12):2826–2835.
   PubMed Web of Science ®Google Scholar